Below copied from IHUB from falconer66a and has in
Post# of 1460
(Total Views: 705)
Posted On: 04/19/2019 4:27:10 PM
Below copied from IHUB from falconer66a and has info on A2-73’s lack of side effects and possible prevention of sleep loss,
Fletch
falconer66a Friday, 04/19/19 03:19:37 PM
Re: baltimorebullet post# 190053 0
Post # of 190060
Anavex 2-73 As A General Soporific
Quote:
I would think more trials would be needed before it could be prescribed like an Ambien type product is.
I implied that if the only therapeutic positive to emerge from any of the three clinical trials were to be pronounced, facilitated sleep for those with central nervous system diseases, where sleep deprivation is a major problem, Anavex 2-73 might well gain approval for this use, alone.
Why would more trials, beyond the three in process now be needed, particularly the three-arm Alzheimer’s trial, with 450 patients? That trial will stack upon the now lengthy, extended results from the relative few Australians continuing to elect to take Anavex 2-73 long after their initial safety and tolerability trial ended.
In that trial, simply no incidences of debilitating or disqualifying adverse events; side effects. In every case, whether in extensive murine (lab rat) tests, or now with human clinical trials, Anavex 2-73 simply has produced no untoward side effects.
This was unexpected. Virtually every drug acting upon the brain or nerves has a host of serious side effects. Anavex 2-73 has none, because it works in nerves very differently from all the other neurotropic drugs. Take Ambien as an example. Check its side effects here: https://www.drugs.com/sfx/ambien-side-effects.html
Ambien is commonly prescribed for those suffering from sleep deprivation. Many taking the drug stop, because the side effects are worse than the sleep deprivation it supposedly treats. Anavex 2-73 has exhibited virtually none of these.
Think there might be a market for a safe, complete soporific drug? Here’s a report that loss of sleep causes a $411,00,000,000 loss in productivity each year in the US: http://fortune.com/2016/11/30/sleep-productiv...1-billion/
https://investorshub.advfn.com/boards/read_ms...=148331812
Fletch
falconer66a Friday, 04/19/19 03:19:37 PM
Re: baltimorebullet post# 190053 0
Post # of 190060
Anavex 2-73 As A General Soporific
Quote:
I would think more trials would be needed before it could be prescribed like an Ambien type product is.
I implied that if the only therapeutic positive to emerge from any of the three clinical trials were to be pronounced, facilitated sleep for those with central nervous system diseases, where sleep deprivation is a major problem, Anavex 2-73 might well gain approval for this use, alone.
Why would more trials, beyond the three in process now be needed, particularly the three-arm Alzheimer’s trial, with 450 patients? That trial will stack upon the now lengthy, extended results from the relative few Australians continuing to elect to take Anavex 2-73 long after their initial safety and tolerability trial ended.
In that trial, simply no incidences of debilitating or disqualifying adverse events; side effects. In every case, whether in extensive murine (lab rat) tests, or now with human clinical trials, Anavex 2-73 simply has produced no untoward side effects.
This was unexpected. Virtually every drug acting upon the brain or nerves has a host of serious side effects. Anavex 2-73 has none, because it works in nerves very differently from all the other neurotropic drugs. Take Ambien as an example. Check its side effects here: https://www.drugs.com/sfx/ambien-side-effects.html
Ambien is commonly prescribed for those suffering from sleep deprivation. Many taking the drug stop, because the side effects are worse than the sleep deprivation it supposedly treats. Anavex 2-73 has exhibited virtually none of these.
Think there might be a market for a safe, complete soporific drug? Here’s a report that loss of sleep causes a $411,00,000,000 loss in productivity each year in the US: http://fortune.com/2016/11/30/sleep-productiv...1-billion/
https://investorshub.advfn.com/boards/read_ms...=148331812
(1)
(0)